The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease (IgG4-RD) in adult patients.

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.

HealthDay News — Use of hormonal contraceptives postpartum is associated with an increased risk for developing postpartum depression, according to a study published online March 31 in JAMA Network ...

Receipt of zoster vaccine reduces probability of new dementia diagnosis over seven-year period by 3.5 percentage points.

Program increases receipt of follow-up colonoscopy among persons aged 50 to 75 years with an abnormal stool test result.

HealthDay News — Health experts are warning that whooping cough, also known as pertussis, is making a dangerous comeback. Cases are rising across the country, and Louisiana recently reported that 2 ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

Tovecimig, formerly known as CTX-009, is a bispecific antibody that blocks the Delta-like ligand 4 and vascular endothelial growth factor A signaling pathways.

The supplemental New Drug Application for the C3G and IC-MPGN indications is supported by data from the phase 3 VALIANT study.

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...